Skip to main content
Premium Trial:

Request an Annual Quote

Second Genome Inks Development Deal with Janssen; Raises Additional $6.5M

NEW YORK (GenomeWeb News) – Microbiome company Second Genome today announced a deal with Johnson & Johnson's Janssen Biotech aimed at microbiome drug discovery.

Second Genome also announced it raised an additional $6.5 million in Series A financing.

Its deal with Janssen is focused on "therapeutic mechanisms in ulcerative colitis mediated by" the microbiome. As part of the deal, the San Bruno, Calif.-based firm will use its microbiome modulation discovery platform to characterize the role of bacterial populations in ulcerative colitis. The firm's proprietary method for generating therapeutic candidates modulates microbe-microbe and microbe-human interactions that influence health and disease, it said.

According to Peter DiLaura, president and CEO of Second Genome, "This collaboration with Janssen will identify mechanisms by which microbial populations in the gut have an impact in ulcerative colitis."

In connection with the agreement, Second Genome will receive an upfront payment and is eligible for potential payments contingent on certain research milestones being achieved. Janssen will also provide support for research activities jointly performed in collaboration with Second Genome.

The Johnson & Johnson Innovation Center and the Immunology Therapeutic Area within Janssen Research & Development will fund the research, Second Genome said.

The company also announced it raised an additional $6.5 million in Series A financing, bringing the total raised in the round to $11.5 million.

The funding will go toward accelerating programs in metabolic disease, inflammation, and infection.

Current investors participated in the latest raise, including Advanced Technology Ventures, Morgenthaler, and Wavepoint Ventures. Individuals, such as company Co-Founder and Chairman Corey Goodman, and board member Matt Winkler, also participated.

Additionally, the company said that former CEO and Co-founder of Envoy Therapeutics Brad Margus has joined Second Genome's board. University of California, San Diego Professor of Medicine Jerrold Olefsky was appointed to the company's scientific advisory board.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.